Christine Duncan, MD, Dana-Farber Cancer Institute


Narsoplimab: The Phase 2 Trial

April 29th 2021

Samer Khaled, MD reviews the design, results, and practical implications of the pivotal phase 2 trial of narsoplimab, a MASP-2 targeted monoclonal antibody under investigation for the treatment of thrombotic microangiopathy associated with hematopoietic stem cell transplantation.

Role of Leptin in the MASP-2 Pathway

April 22nd 2021

Jeffrey Laurence, MD, discusses the role of leptin in the MASP-2 pathway as well as coagulation and complement pathways.

TA-TMA Treatment: Alternative Medications

April 22nd 2021

The panel reviews therapeutic options for managing transplant-associated thrombotic microangiopathy and the challenges associated with currently existing agents.

Practical Experience in TA-TMA Interventions

April 15th 2021

Experts in the field of hematopoietic stem cell transplantation provide their views and experiences with various interventions for managing transplant-associated thrombotic microangiopathy.

Interventions Used for TA-TMA

April 15th 2021

Jeffrey Laurence, MD, reviews the available interventions used to mitigate or treat transplant-associated thrombotic microangiopathy.

Challenges of Accurate Diagnosis of TA-TMA After Hematopoietic Stem Cell Transplant

April 8th 2021

A panel of experts recall the challenges of accurate early detection of transplant-associated thrombotic microangiopathy and its importance for improved patient outcomes.

Relationship Between TA-TMA Development and GVHD

April 8th 2021

The panel considers the development, morbidity, and survival of transplant-associated thrombotic microangiopathy associated with GVHD (graft-versus-host disease).

Risk Factors Associated With TA-TMA

April 1st 2021

Jeffrey Laurence, MD, reviews the risk factors for developing transplant-associated thrombotic microangiopathy, and the panel discusses how risk affects their decision to change or modify treatment regimens.

Uncontrolled Versus Self-Limited TA-TMA

April 1st 2021

Parameswaran Hari, MD, and Christine Duncan, MD, discuss the differences between uncontrolled vs self-limited transplant-associated thrombotic microangiopathy.

Time Frame for Development of TA-TMA

March 25th 2021

The expert panel considers the time frame of transplant-associated thrombotic microangiopathy, the subtle signs to pay attention to, and testing for proteinuria.